Twenty-one patients with various forms and stages of systemic scleroderma were treated with azathioprine, an immunosuppressive agent. Eight of these patients were judged to be improved subjectively and by clinical evaluation during the course of treatment. Seven patients were unchanged, two had progression of their disease and one was lost from the study. None of the patients died during the course of the study. In three patients, a febrile reaction required cessation of therapy. Other toxic symptoms were noted but their mild nature did not preclude continuing therapy. The difficulties of objective evaluation and establishment of a proper control study group is reviewed. These results do not establish unequivocal evidence that this drug or treatment approach is successful in the control of systemic scleroderma. An evaluation in a larger series for a more prolonged time is indicated.
Jansen GT, Barraza DF, Ballard JL, Honeycutt WM, Dillaha CJ. Generalized SclerodermaTreatment With an Immunosuppressive Agent. Arch Dermatol. 1968;97(6):690–698. doi:10.1001/archderm.1968.01610120080013
Customize your JAMA Network experience by selecting one or more topics from the list below.